OverviewSuggest Edit

Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments and without the side effects of chemotherapy drugs. The Company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.

TypePublic
Founded1998
HQBethesda, US
Websitenwbio.com
Employee Ratings0

Latest Updates

Employees (est.) (Feb 2019)14(+40%)
Revenue (FY, 2017)$336 K(-46%)

Key People/Management at Northwest Biotherapeutics

Linda F. Powers

Linda F. Powers

CEO
Marnix L. Bosch

Marnix L. Bosch

CTO
Anthony Maida

Anthony Maida

COO
Alton L. Boynton

Alton L. Boynton

CSO
Show more

Northwest Biotherapeutics Office Locations

Northwest Biotherapeutics has an office in Bethesda
Bethesda, US (HQ)
4800 Montgomery Ln
Show all (1)
Report incorrect company information

Northwest Biotherapeutics Financials and Metrics

Northwest Biotherapeutics Revenue

Northwest Biotherapeutics's revenue was reported to be $336 k in FY, 2017
USD

Revenue (Q3, 2018)

453.0k

Net income (Q3, 2018)

12.6m

EBIT (Q3, 2018)

(9.3m)

Market capitalization (9-Oct-2018)

234.2m

Cash (30-Sep-2018)

248.0k

EV

238.0m
Northwest Biotherapeutics's current market capitalization is $234.2 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

809.0k1.7m623.0k336.0k

General and administrative expense

24.9m10.9m12.5m

R&D expense

43.9m103.1m60.1m33.5m

Operating expense total

56.3m128.0m79.9m55.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

400.0k582.0k391.0k291.0k236.0k157.0k159.0k68.0k88.0k148.0k132.0k278.0k453.0k

General and administrative expense

9.8m4.3m4.3m6.5m4.6m3.0m3.3m3.0m3.0m14.4m3.5m

R&D expense

12.8m20.0m21.5m22.7m29.4m9.2m13.4m8.7m5.0m5.5m9.7m4.7m5.3m4.3m

Operating expense total

15.9m23.7m25.4m27.2m39.2m13.5m17.7m15.2m25.7m12.0m10.8m14.3m8.9m20.6m9.8m
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Net Income

(65.8m)(114.7m)(80.2m)(73.1m)

Depreciation and Amortization

11.0k56.0k189.0k439.0k

Accounts Payable

766.0k3.9m1.0m501.0k

Cash From Operating Activities

(37.8m)(78.6m)(55.7m)(36.5m)
USDY, 2018

EV/EBIT

-25.5 x

EV/CFO

-11.7 x

Financial Leverage

-1 x
Show all financial metrics
Report incorrect company information

Northwest Biotherapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Northwest Biotherapeutics News and Updates

Product Overview and Scope of Worldwide Castration Resistant Prostate Cancer Treatment Market forecast 2025 | TOP Key Players - Active Biotech, Diagnocure, Glaxosmithkline, Northwest Biotherapeutics, Millennium Pharmaceuticals, Hologic, Spectrum Pharmaceu

Summary: A new market study, titled “Discover Global Castration Resistant Prostate Cancer Treatment Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

Northwest Biotherapeutics Blogs

Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma

Presented at Society for Neuro-Oncology Conference Data Continuing to Mature, Particularly Regarding Long Tail of Survival Curve BETHESDA, Md., November 19, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapie... The post…

NW Bio Announces $5 Million Bridge Funding

Notes With 50% Warrants Exercisable at $0.35 Per Share BETHESDA, Md., November 13, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on November 7, 2018, it co... The post…

Dr. Marnix Bosch’s Presentation on Clinical Development of Dendritic Cell-Based Immunotherapy for Cancer at Immuno-Oncology Summit

Download the Presentation. View article in Clinical Cancer Research.... The post Dr. Marnix Bosch’s Presentation on Clinical Development of Dendritic Cell-Based Immunotherapy for Cancer at Immuno-Oncology Summit appeared first on Northwest Biotherapeutics.

NW Bio Announces Upcoming Presentation By Dr. Marnix Bosch At Immuno-Oncology Summit

BETHESDA, Md., August 28, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio is presenting at 8:00 pm Wednes... The post…

Webcast: Dr. Marnix Bosch’s Presentation on DCVax® Personalized Dendritic Cell Vaccines from ASCO 2018

View the recorded webcast.... The post Webcast: Dr. Marnix Bosch’s Presentation on DCVax® Personalized Dendritic Cell Vaccines from ASCO 2018 appeared first on Northwest Biotherapeutics.

Webcast: Dr. Marnix Bosch’s Presentation on DCVax® Personalized Dendritic Cell Vaccines from ASCO 2018

... The post Webcast: Dr. Marnix Bosch’s Presentation on DCVax® Personalized Dendritic Cell Vaccines from ASCO 2018 appeared first on Northwest Biotherapeutics.
Show more

Northwest Biotherapeutics Frequently Asked Questions

  • When was Northwest Biotherapeutics founded?

    Northwest Biotherapeutics was founded in 1998.

  • Who are Northwest Biotherapeutics key executives?

    Northwest Biotherapeutics's key executives are Linda F. Powers, Marnix L. Bosch and Anthony Maida.

  • How many employees does Northwest Biotherapeutics have?

    Northwest Biotherapeutics has 14 employees.

  • What is Northwest Biotherapeutics revenue?

    Latest Northwest Biotherapeutics annual revenue is $336 k.

  • What is Northwest Biotherapeutics revenue per employee?

    Latest Northwest Biotherapeutics revenue per employee is $24 k.

  • Who are Northwest Biotherapeutics competitors?

    Competitors of Northwest Biotherapeutics include Merrimack Pharmaceuticals, TESARO and AVEO Pharmaceuticals.

  • Where is Northwest Biotherapeutics headquarters?

    Northwest Biotherapeutics headquarters is located at 4800 Montgomery Ln, Bethesda.

  • Where are Northwest Biotherapeutics offices?

    Northwest Biotherapeutics has an office in Bethesda.

  • How many offices does Northwest Biotherapeutics have?

    Northwest Biotherapeutics has 1 office.